Susheel Jethanand Nara

This inventor holds 28 USPTO granted patents and 5 published patent applications and 10 EPO patents, primarily in Kinase Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Syngene International Limited. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Susheel Jethanand Nara. Retrieved from https://idiyas.com/inventor/susheel-jethanand-nara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 10 (Patent Applications = 23)

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 42(Granted Patents)

Location History:

Chembur, IN (2019)
Bengaluru, IN (2014 - 2024)
Mumbai, IN (2017 - 2024)

Company Filing History:

31 out of 3,745

Bristol-Myers Squibb Compnay

patents

3 out of 7

Syngene International Limited

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Farnesoid X Receptor

Indoleamine Inhibitors

Small Molecule Inhibitors

Biaryl Kinase Inhibitors

Bicyclic Compounds

Aryl Lactam Kinase

Heterocyclic Compounds

Quinoline-based Inhibitors

Aryl Amide-based Kinase

Fused Pyridines

IDO Inhibitors

Substituted Compounds

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319676 - Substituted amide compounds useful as farnesoid X receptor modulators (2025-06-03),

2. 12286424 - Small molecule inhibitors of galectin-3 (2025-04-29),

3. 12275720 - Small molecule inhibitors of galectin-3 (2025-04-14),

4. 12269819 - Small molecule inhibitors of Galectin-3 (2025-04-08),

5. 12227496 - Substituted bicyclic compounds as farnesoid X receptor modulators (2025-02-18),

6. 12145927 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2024-11-19),

7. 12059420 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2024-08-13),

8. 12030835 - Substituted amide compounds useful as farnesoid X receptor modulators (2024-07-09),

9. 11713312 - Substituted bicyclic compounds as farnesoid X receptor modulators (2023-08-01),

10. 11337970 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2022-05-24),

11. 11254663 - Substituted bicyclic compounds as farnesoid X receptor modulators (2022-02-22),

12. 11253525 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2022-02-22),

13. 10959986 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2021-03-30),

14. 10730863 - Bridged bicyclic compounds as farnesoid X receptor modulators (2020-08-04),

15. 10544120 - Biaryl kinase inhibitors (2020-01-28),

Title: Contributions of Susheel Jethanand Nara to Pharmaceutical Innovations

Introduction: Susheel Jethanand Nara is a prominent inventor based in Bengaluru, India, with a remarkable portfolio of 24 patents. His work primarily focuses on developing innovative compounds that target critical receptors and enzymes in the human body, paving the way for new treatments for various diseases.

Latest Patents: Among Susheel’s notable inventions are two groundbreaking patents. The first patent involves "Substituted bicyclic compounds as farnesoid X receptor modulators." This invention discloses compounds aimed at modulating the activity of the farnesoid X receptor (FXR), which is vital in treating disorders associated with FXR dysregulation. These compounds, alongside pharmaceutical compositions, have potential applications in managing conditions such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

The second patent details "Inhibitors of indoleamine 2,3-dioxygenase and methods of their use." This patent presents compounds that serve as inhibitors of indoleamine 2,3-dioxygenase (IDO). These compounds are significant for their therapeutic potential in treating proliferative disorders, including cancer, viral infections, and autoimmune diseases.

Career Highlights: Throughout his career, Susheel has contributed to the pharmaceutical field by collaborating with reputable organizations. Notably, he has worked at Bristol-Myers Squibb Company and Syngene International Limited, where he developed various innovative therapeutic solutions.

Collaborations: Susheel has worked closely with several talented professionals, including Soodamani Thangavel and Srinivas Cheruku. Their collaborative efforts have fueled advancements in the research and development of medical therapies and compounds.

Conclusion: Susheel Jethanand Nara's contributions through his inventive patents highlight his significant impact on the pharmaceutical industry. His innovative approaches to developing new therapeutic compounds not only showcase his expertise but also his commitment to advancing healthcare solutions for various medical challenges.

Profile summary based on public USPTO records.